<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="models of chikungunya infection. Two of them, the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, have a"/>
 <result pre="Infected HeLa cells were exposed to cerulenin, TOFA, pimozide, W7," exact="tivozanib" post="or vehicle only (DMSO). All the tested inhibitors significantly"/>
 <result pre="for antiviral drug development. To analyse the antiviral effect of" exact="tivozanib" post="(targeting FLT4) in vivo, 7-day-old C57BL/6 mice were treated"/>
 <result pre="for 2 days and infected with CHIKV at day 9." exact="Tivozanib" post="administration was continued for 21 days (Fig. 6c). Tivozanib"/>
 <result pre="9. Tivozanib administration was continued for 21 days (Fig. 6c)." exact="Tivozanib" post="caused a significant reduction in mortality of CHIKV-infected mice"/>
 <result pre="impact on body weight gain (Fig. 6f,g; P=0.0133, two-sided t-test)." exact="Tivozanib" post="treatment also significantly reduced CHIKV viral load in different"/>
 <result pre="we tested the in vivo efficacy of the calmodulin inhibitor" exact="pimozide" post="and the fatty acid synthesis inhibitor TOFA, which have"/>
 <result pre="we combined drugs to improve antiviral activity. We focused on" exact="pimozide" post="and TOFA, since they both demonstrated an antiviral effect"/>
 <result pre="with CHIKV for 1 h. In comparison with monotherapy, TOFA and" exact="pimozide" post="combination resulted in increased inhibition of CHIKV infection rate"/>
 <result pre="drug combination in vivo, in adult mice therapeutically treated with" exact="pimozide" post="and TOFA alone or in combination. Importantly, pimozide and"/>
 <result pre="treated with pimozide and TOFA alone or in combination. Importantly," exact="pimozide" post="and TOFA combination caused a significant reduction in CHIKV"/>
 <result pre="the potential for broadly active, host-directed, antiviral therapies (for example," exact="pimozide" post="that had an antiviral effect both for CHIKV and"/>
 <result pre="6-chloroharmine and 31 mg (0.27 mmol) of potassium tert-butanolate in 5 ml of" exact="anhydrous" post="DMSO was stirred at 80 °C for 30 min, then 0.13 ml"/>
 <result pre="(10%) and extracted with ethyl acetate. The organic layer was" exact="dried" post="over sodium sulfate and evaporated. The residue was purified"/>
 <result pre="testing The following drugs were used following solubilization in DMSO:" exact="tivozanib" post="(Selleck, 43.96 mM stock), cerulenin (TEBU, 50 mM stock), KH-CB19 (R&amp;amp;D"/>
 <result pre="50 mM stock), KH-CB19 (R&amp;amp;D Systems, 10 mM stock), bafilomycin (50 μM stock)," exact="pimozide" post="(10 mM stock), W7 (53 mM stock), TOFA (10 mM stock), BMS-303141"/>
 <result pre="mice (0.5 mg kg−1, per os) were infected as described above, whereas" exact="pimozide" post="(20 mg kg−1, via os)- and TOFA (25 mg kg−1, via intraperitoneal)-treated mice"/>
 <result pre="were handled as follows: for experiments shown in Fig. 6," exact="tivozanib" post="(Selleck) was first dissolved in DMSO (40 mg ml−1) and then"/>
 <result pre="diluted in 0.5% methylcellulose to a final concentration of 0.25 mg ml−1;" exact="pimozide" post="(Sigma) was dissolved (25 mg ml−1) in N-methyl-2-pyrrolidone (NMP) and then"/>
 <result pre="of 5 mg ml−1. For experiments shown in Fig. 7d,e, TOFA and" exact="pimozide" post="were dissolved in DMSO (independently or in combination) to"/>
 <result pre="Oncol. Rep.13, 103–111 (2011).21318618 NelsonE. A.et al.. The STAT5 inhibitor" exact="pimozide" post="displays efficacy in models of acute myelogenous leukemia driven"/>
 <result pre="50) for 1 h and treated with cerulenin (50 μM), TOFA (25 μM)," exact="pimozide" post="(pimo, 10 μM), W7 (20 μM), tivozanib (tivo, 5 μM) or vehicle"/>
 <result pre="with cerulenin (50 μM), TOFA (25 μM), pimozide (pimo, 10 μM), W7 (20 μM)," exact="tivozanib" post="(tivo, 5 μM) or vehicle alone for an additional 7 h."/>
 <result pre="young mouse model used for tivozanib. (d–f) Effect of daily" exact="tivozanib" post="(tivo) treatment on C57BL/6 mouse survival, paralysis and body"/>
 <result pre="infection in the indicated organs obtained from mice treated with" exact="tivozanib" post="as in c (n=9 for all data sets). (i,j)"/>
 <result pre="used and viral titres measured in C57BL/6 mice treated with" exact="pimozide" post="(pimo, per os, n=15 for both data sets) or"/>
 <result pre="days; i.p., intraperitoneal; NS, not significant. Figure 7 Impact of" exact="pimozide" post="and TOFA combination on CHIKV replication in vitro and"/>
 <result pre="Therapeutic index Fatty acid synthesis TOFA 0.15 &amp;gt; 60* NT" exact="Orlistat" post="0.82 8.67 10.57 Cerulenin 3 7.57 2.53 vATPase Bafilomycin"/>
 <result pre="acid 0.58 2.68 4.65 Calmodulin signalling TAE684 0.15 2.07 14.28" exact="Pimozide" post="0.28 19.18 69.75 Perphenazine 0.63 24.23 38.28 6-Hydroxyflavone 2.6"/>
 <result pre="Calmodulin signalling TAE684 0.15 2.07 14.28 Pimozide 0.28 19.18 69.75" exact="Perphenazine" post="0.63 24.23 38.28 6-Hydroxyflavone 2.6 &amp;gt; 60 NT Prenylamine"/>
 <result pre="38.28 6-Hydroxyflavone 2.6 &amp;gt; 60 NT Prenylamine 2.39 16.53 6.91" exact="Felodipine" post="3.24 12.08 3.73 FLT4 Alsterpaullone 0.002 44.38* NT Pazopanib"/>
 <result pre="44.38* NT Pazopanib 0.13 1.32* NT Axitinib 0.3 0.34* NT" exact="Tivozanib" post="0.8 8.34* NT Sorafenib 1.11 18.24 16.42 Linifanib 2.15"/>
 <result pre="1.32* NT Axitinib 0.3 0.34* NT Tivozanib 0.8 8.34* NT" exact="Sorafenib" post="1.11 18.24 16.42 Linifanib 2.15 &amp;gt; 60 NT CHIKV,"/>
</results>
